Medication info

Olmesartan Medoxomil and Rosuvastatin Tablets 20/20 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
White or light yellow round film-coated tablets
Packaging
30 tablets/box [30 tablets (10 tablets/PTP x 3)]
Approval status
Expired

MFDS item code 202100102 · Approved 2021.01.06

This product's status changed to Expired on 2026.01.06. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis progression and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time every day (e.g., in the morning), if possible. For patients who may have intravascular volume depletion (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose while their condition is closely monitored. 2. Elderly patients No dosage adjustment is required when this medicine is administered to elderly patients aged 65 years or older. Although no overall differences in efficacy and safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dosage adjustment is required for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg once daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients No dosage adjustment is required. 3. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special caution should be exercised when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
The safety and efficacy in children under 18 years of age have not been established.

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis progression and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbeta-lipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is indicated for patients using both Olmesartan Medoxomil and Rosuvastatin. Olmesartan Medoxomil is primarily used to treat essential hypertension. Rosuvastatin is used as an adjunct in patients with hypercholesterolemia, hyperlipidemia, and familial hypercholesterolemia when diet and exercise alone are insufficient. Additionally, Rosuvastatin lowers total cholesterol and LDL cholesterol levels, helping to delay the progression of atherosclerosis and reduce cardiovascular risks. Particularly, it is expected to reduce the risk of stroke, myocardial infarction, and arterial revascularization in high-risk patients with elevated high-sensitivity C-reactive protein. Therefore, this medication improves the prevention of cardiovascular diseases by managing both hypertension and hyperlipidemia simultaneously.

How to take

Adult dose

This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time every day (e.g., in the morning), if possible. For patients who may have intravascular volume depletion (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose while their condition is closely monitored. 2. Elderly patients No dosage adjustment is required when this medicine is administered to elderly patients aged 65 years or older. Although no overall differences in efficacy and safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dosage adjustment is required for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg once daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients No dosage adjustment is required. 3. Patients with renal impairment No dosage adjustment is required for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special caution should be exercised when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

The safety and efficacy in children under 18 years of age have not been established.

Precautions

This drug can cause serious harm to the fetus and newborn when taken during the second and third trimester of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to individuals with known allergies to its ingredients, to pregnant or potentially pregnant women, or to breastfeeding women. Use is contraindicated in patients with severely impaired renal function, those undergoing renal dialysis, patients with severe liver impairment, and those with biliary obstruction. Patients with a history of muscle disorders or those prone to muscle issues should avoid high-dose administration of this medication, especially the 40 mg dose which is contraindicated. This drug contains lactose and should not be used by patients with lactose intolerance or related genetic disorders. In patients with low blood pressure or decreased salt or blood volume, hypotension may occur if administered, and appropriate treatment is required immediately if hypotension symptoms arise. Patients who are dependent on renal function may experience worsening renal function, thus routine blood tests should be done to monitor renal function periodically. As there is a risk of hyperkalemia, serum potassium levels should be monitored regularly, and caution is needed in patients with heart or lung problems. This medication may affect liver function, so patients with a history of liver disease or those consuming excessive alcohol should have regular liver function tests. In cases of muscle pain or weakness, the healthcare provider should be notified immediately, and if severe, medication should be stopped. This drug may interact with other medications; special caution is required particularly when co-administered with potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, specific antivirals, and fibrates. Pregnant or breastfeeding women should not take this drug, and women who could become pregnant should use appropriate contraception. Extra caution is required when administering this drug to children under 18 years of age and to elderly patients over 65 years, as elderly patients may show increased drug concentration in the body. In case of overdose, symptoms such as hypotension and palpitations may occur, and appropriate treatment should be administered through liver function and muscle-related tests. This medication should be kept out of the reach of children and should not be transferred to another container.

Side effects

Increased ALT, Increased AST, Elevated blood creatinine, Decreased creatinine clearance, Headache, Dizziness, Sensory impairment, Neuropathy, Drowsiness, Gastroesophageal reflux disease, Constipation, Cavities, Indigestion, Gastric ulcer, Gastritis, Gastroenteritis, Musculoskeletal rigidity, Atrial fibrillation, Hypoglycemia, Chest pain, Tooth extraction, Chest discomfort, Peripheral edema, Vertigo, Abdominal pain, Nausea, Palpitations, Hypercholesterolemia, Hyperlipidemia, Hyperuricemia, Arthralgia, Arthritis, Myalgia, Rash, Facial edema, Weakness, Angioedema, Anaphylactic reaction, Vomiting, Chronic malabsorption syndrome, Mesenteric edema, Rhabdomyolysis, Hyperkalemia, Acute renal failure, Hair loss, Itching, Urticaria, Autoimmune hepatitis, Dizziness (including positional dizziness), Palpitations, Increased blood pressure, Low back pain, Increased serum creatinine, Diarrhea, Cough, Epistaxis, Upper respiratory tract infection, Asthma, Hypersensitivity reaction including angioedema, Diabetes, Constipation, Nausea, Abdominal pain, Pancreatitis, Itching, Rash, Urticaria, Myalgia, Myopathy, Rhabdomyolysis, Weakness, Polyneuropathy, Amnesia, Peripheral neuropathy, Dyspnea, Thrombocytopenia, Jaundice, Hepatitis, Stevens-Johnson syndrome, Drug reaction with eosinophilia and systemic symptoms (DRESS), Lupus-like syndrome, Muscle rupture, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Interstitial lung disease, Sexual dysfunction, Gynecomastia, Fatal and non-fatal liver failure, Cognitive impairment, Severe muscle weakness, Ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture; therefore, it must be stored in a sealed container. The storage temperature should be maintained between 1°C and 30°C at room temperature to safely preserve the efficacy of the drug.

Appearance and packaging

Appearance

White or light yellow round film-coated tablets

Package unit

30 tablets/box [30 tablets (10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.